Alpha 1 Biomedicals, SciClone news

The companies settled their dispute over ALBM's Thymosin alpha 1 by granting SCLN virtual control over the product in return for up to $35 million in royalty payments to ALBM.

The companies dropped all remaining issues and terminated their arbitration proceeding without either side paying damages. ...